RUBY - Rubius Therapeutics to present early-stage RTX-240 study results at AACR

Rubius Therapeutics (RUBY) announces that initial clinical results from its ongoing Phase 1/2 study of RTX-240 in advanced solid tumors will be presented at the American Association for Cancer Research ((AACR)) Virtual Annual Meeting.Posters will be available online tomorrow on the AACR website, and the data included in the poster will be based on a data cutoff date of February 28, 2021."The clinical data shared to date demonstrate that RTX-240 has the ability to activate and expand a patient’s own immune system to fight cancer, leading to clinical responses in certain patients with advanced solid tumors," Omid Hamid, Chief of Translational Research and Immunotherapy said.The company also said that it intends to initiate a new Phase 1 arm to evaluate RTX-240 in combination with anti-PD-1 therapy in advanced solid tumors during the second half of 2021.#AACR21

For further details see:

Rubius Therapeutics to present early-stage RTX-240 study results at AACR